Chlorproguanil hydrochloride-dapsone-artesunate

Chlorproguanil-dapsone-artesunate (abbreviated CDA) is a new antimalarial treatment that entered Phase III clinical trials in 2006.

It consists of chlorproguanil hydrochloride, dapsone, and artesunate. (It can also be interpreted as Lapdap+artesunate).

It is being compared against artemether-lumefantrine (Coartem) and against chlorproguanil-dapsone Lapdap. This drug is being developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine.^[1]

References

↑ Das P (2006). "Promising anti-malarial enters phase II studies.". Lancet Infect Dis 6 (9): 551. doi:10.1016/S1473-3099(06)70571-0.

External links

Special Programme for Research and Training in Tropical Diseases

Antiparasitics – antiprotozoal agents – Chromalveolate antiparasitics (P01)

Alveo-
late

Apicom-
plexa

Conoidasida/
(Coccidiostats)

Cryptosporidiosis	thiazolide (nitazoxanide)

Isosporiasis	trimethoprim/sulfamethoxazole^#

Toxoplasmosis	pyrimethamine sulfadiazine

Aconoidasida

Malaria

Individual
agents

Hemozoin
inhibitors

aminoquinolines	(4-): amodiaquine^# chloroquine^# Tafenoquine (8-): primaquine^# pamaquine

4-methanolquinolines	mefloquine^# quinine^# quinidine

Other	lumefantrine combined with artemether halofantrine

Antifolates

DHFR inhibitors (antifols)	pyrimethamine proguanil^# chlorproguanil biguanides

Sulfonamides	sulfadoxine sulfamethoxypyrazine

Coformulation	sulfadoxine/pyrimethamine (SP)^#

Sesquiterpene
lactones

Other

Combi-
nations

Fixed-dose (coformulated) ACTs	artemether/lumefantrine^# artesunate/amodiaquine (ASAQ) artesunate/mefloquine (ASMQ) dihydroartemisinin/piperaquine artesunate/pyronaridine

Other combinations (not co-formulated)	artesunate/SP artesunate/mefloquine quinine/tetracycline quinine/doxycycline quinine/clindamycin

Babesiosis

clindamycin

Cilio-
phora

Balantidiasis: Tetracycline

Hetero-
kont

Blastocystosis: Metronidazole

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Sunday, August 16, 2009. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.